PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

References

• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015 Apr; 62(1 Suppl):S47–64.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J, et al. MAFLD: a Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1999–2014 e1.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011 Jun 24;332(6037):1519–1523.
   PubMed Web of Science ®Google Scholar
• Cholankeril G, Wong RJ, Hu M, et al. Liver Transplantation for Nonalcoholic Steatohepatitis in the US: temporal Trends and Outcomes. Dig Dis Sci. 2017 Oct;62(10):2915–2922.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 Jul;68(1):349–360.
   PubMed Web of Science ®Google Scholar
• Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017Jan;37 Suppl 1:81–84.
   PubMed Web of Science ®Google Scholar
• Stender S, Kozlitina J, Nordestgaard BG, et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017 Jun;49(6):842–847.
   PubMed Web of Science ®Google Scholar
• Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016 Mar;63(3):764–775.
   PubMed Web of Science ®Google Scholar
• Loomba R, Seguritan V, Li W, et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017 May 2;25(5):1054–1062 e5.
   PubMed Web of Science ®Google Scholar
• Del Chierico F, Nobili V, Vernocchi P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017 Feb;65(2):451–464.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017 Jul;46(2):85–95.
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008 Dec;40(12):1461–1465.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Castano GO, Burgueno AL, et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res. 2009 Oct;50(10):2111–2116.
   PubMed Web of Science ®Google Scholar
• Trepo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol. 2020 Jun;72(6):1196–1209.
   PubMed Web of Science ®Google Scholar
• Bianco C, Casirati E, Malvestiti F, et al. Genetic predisposition similarities between NASH and ASH: identification of new therapeutic targets. JHEP Rep. 2021 Jun;3(3):100284. ** A comprehensive review on the new therapeutic targets to treat both NASH and ASH.
   PubMedGoogle Scholar
• Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020 Aug 22;396(10250):565–582.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–161.
   PubMed Web of Science ®Google Scholar
• Sharpton SR, Schnabl B, Knight R, et al. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metab. 2021 Jan 5;33(1):21–32.
   PubMed Web of Science ®Google Scholar
• Idalsoaga F, Kulkarni AV, Mousa OY, et al. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: two Intertwined Entities. Front Med (Lausanne). 2020;7:448.
   PubMed Web of Science ®Google Scholar
• Arrese M, Arab JP, Barrera F, et al. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis. 2021 Jul 7. doi:https://doi.org/10.1055/s-0041-1730927
   Google Scholar
• Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int. 2020 May;40(5):1016–1017.
   PubMed Web of Science ®Google Scholar
• Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020 Dec;40(12):3018–3030.
   PubMed Web of Science ®Google Scholar
• Mendez-Sanchez N, Diaz-Orozco LE. Editorial: international Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit. 2021 Jul 12;27:e933860
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol. 2021 Apr;15(4):345–352.
   PubMed Web of Science ®Google Scholar
• Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009 Nov;58(11):2616–2623.
   PubMed Web of Science ®Google Scholar
• Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010 Apr;51(4):1209–1217.
   PubMed Web of Science ®Google Scholar
• Valenti L, Colombo M, Fargion S. Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. J Hepatol. 2011Dec;55(6):1470–1471. author reply 1471-2.
   PubMed Web of Science ®Google Scholar
• Trepo E, Romeo S, Zucman-Rossi J, et al. PNPLA3 gene in liver diseases. J Hepatol. 2016 Aug;65(2):399–412.
   PubMed Web of Science ®Google Scholar
• Unalp-Arida A, Ruhl CE. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population. Hepatology. 2020 Mar;71(3):820–834. ** A comprehensive study demonstrating the association between PNPLA3 p.I148M variant with increased liver disease mortality.
   PubMed Web of Science ®Google Scholar
• Jamialahmadi O, Bianco C, Pelusi S, et al. Reply to: “Polygenic risk score: a promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease.” J Hepatol. 2021 Jun;74(6):1494–1496.
   PubMed Web of Science ®Google Scholar
• Carlsson B, Linden D, Brolen G, et al. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020 Jun;51(12):1305–1320.
   PubMed Web of Science ®Google Scholar
• Donati B, Motta BM, Pingitore P, et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology. 2016 Mar;63(3):787–798.
   PubMed Web of Science ®Google Scholar
• Pelusi S, Baselli G, Pietrelli A, et al. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Sci Rep. 2019 Mar 6;9(1):3682.
   PubMedGoogle Scholar
• Valenti L, Dongiovanni P. Mutant PNPLA3 I148M protein as pharmacological target for liver disease. Hepatology. 2017 Oct;66(4):1026–1028.
   PubMed Web of Science ®Google Scholar
• Abul-Husn NS, Cheng X, Li AH, et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018 Mar 22;378(12):1096–1106. * First study demonstrating a strong protective role for HSD17B13 against steatohepatitis in patients with PNPLA3 p.I148M variants.
   PubMed Web of Science ®Google Scholar
• Ma Y, Belyaeva OV, Brown PM, et al. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology. 2019 Apr;69(4):1504–1519.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Garaycoechea M, Flichman D, et al. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease. J Lipid Res. 2019 Jan;60(1):176–185.
   PubMed Web of Science ®Google Scholar
• Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem. 2011 Oct 28;286(43):37085–37093.
   PubMed Web of Science ®Google Scholar
• Pingitore P, Pirazzi C, Mancina RM, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta. 2014 Apr 4;1841(4):574–580.
   PubMed Web of Science ®Google Scholar
• Luukkonen PK, Nick A, Holtta-Vuori M, et al. Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight. 2019 Aug 22;4(16). doi: https://doi.org/10.1172/jci.insight.127902.
   Google Scholar
• Tilson SG, Morell CM, Lenaerts AS, et al. Modelling PNPLA3-Associated Non-Alcoholic Fatty Liver Disease Using Human Induced Pluripotent Stem Cells. Hepatology. 2021 Jul 20. DOI:https://doi.org/10.1002/hep.32063
   Google Scholar
• BasuRay S, Wang Y, Smagris E, et al. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A. 2019 May 7;116(19):9521–9526. * This study shows two important therapeutic approaches to treat NAFLD. 1) PNPLA3 silencing via RNAi and 2) accelerating degradation of PNPLA3 by promoting its association with an E3 ligase using the PROTAC system.
   PubMed Web of Science ®Google Scholar
• BasuRay S, Smagris E, Cohen JC, et al. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology. 2017 Oct;66(4):1111–1124.
   PubMed Web of Science ®Google Scholar
• Valenti LV, Cherubini A. To be, or not to be: the Quest for PNPLA3 p.I148M function. Hepatology. [2021 Aug 12]. doi:https://doi.org/10.1002/hep.32096
   Google Scholar
• Mantovani A, Taliento A, Zusi C, et al. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: clinical and experimental findings. Liver Int. 2020 May;40(5):1130–1141. * An interesting study demonstrating that the carriage of the PNPLA3 rs738409 polymorphism was closely associated with increased incidence of CKD in patients with T2DM.
   PubMed Web of Science ®Google Scholar
• Dubuquoy C, Robichon C, Lasnier F, et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J Hepatol. 2011 Jul;55(1):145–153.
   PubMed Web of Science ®Google Scholar
• Liang H, Xu J, Xu F, et al. The SRE Motif in the Human PNPLA3 Promoter (−97 to −88 bp) Mediates Transactivational Effects of SREBP-1c. J Cell Physiol. 2015 Sep;230(9):2224–2232.
   PubMed Web of Science ®Google Scholar
• Perttila J, Huaman-Samanez C, Caron S, et al. PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. Am J Physiol Endocrinol Metab. 2012 May 15;302(9):E1063–9.
   PubMed Web of Science ®Google Scholar
• Kim KY, Jang HJ, Yang YR, et al. SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy. Sci Rep. 2016 Oct 21;6:35732.
   PubMed Web of Science ®Google Scholar
• Yang A, Mottillo EP, Mladenovic-Lucas L, et al. Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes. Nat Metab. 2019 May;1(5):560–569. ** Shows that PNPLA3 compete with PNPLA2 to bind ABHD5, playing a negative transactivation activity on other lipases in hepatocytes and triggering TAG accumulation in lipid droplets.
   PubMedGoogle Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259–293.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Wang S, Vickers TA, et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol. 2017 Mar;35(3):230–237.
   PubMed Web of Science ®Google Scholar
• Kim Y, Jo M, Schmidt J, et al. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models. Mol Ther. 2019 Sep 4;27(9):1547–1557.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020 Oct 21;41(40):3936–3945.
   PubMed Web of Science ®Google Scholar
• Kumashiro N, Beddow SA, Vatner DF, et al. Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance. Diabetes. 2013 Jul;62(7):2183–2194.
   PubMed Web of Science ®Google Scholar
• Banini BA, Kumar DP, Cazanave S, et al. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis. Hepatology. 2021 Apr;73(4):1290–1306. ** In this study on mice, the authors show that PNPLA3 p.I148M promotes steatosis and NASH via metabolic reprogramming and increased ceramides. ** In this study on mice, the authors show that PNPLA3 p.I148M promotes steatosis and NASH via metabolic reprogramming and increased ceramidesdependent STAT3 phosphorylation accompanied by an increased stellate cell fibrogenic activity.
   PubMed Web of Science ®Google Scholar
• Linden D, Ahnmark A, Pingitore P, et al. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Mol Metab. 2019 Apr;22:49–61. * This study conducted in mice, provides the first evidence that a Pnpla3 ASO therapy can improve all features of NAFLD.
   PubMed Web of Science ®Google Scholar
• Scharner J, Aznarez I. Clinical Applications of Single-Stranded Oligonucleotides: current Landscape of Approved and In-Development Therapeutics. Mol Ther. 2021 Feb 3;29(2):540–554. ** A comprehensive review of the recent applications of antisense oligonucletoide in precision medicine.
   PubMed Web of Science ®Google Scholar
• Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine. 2012;7:2181–2195.
   PubMed Web of Science ®Google Scholar
• Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective. Toxicol Pathol. 2015 Jan;43(1):78–89.
   PubMed Web of Science ®Google Scholar
• Rae-Whitcombe SM, Kennedy D, Voyles M, et al. Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin. Biochem Biophys Res Commun. 2010 Nov 26;402(4):767–772.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib J, Roberts AW, et al. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia. 2018 Apr;32(4):1035–1038.
   PubMed Web of Science ®Google Scholar
• Schwartz BE, Rajagopal V, Smith C, et al. Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings. Cells. 2020 Oct 7;9(10). doi:https://doi.org/10.3390/cells9102247.** Significant study showing that momelotinib, previously used to treat myelofibrosis has a potential NASH therapeutic effect targeting PNPLA3.
   Google Scholar
• Liu WY, Eslam M, Zheng KI, et al. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. J Clin Transl Hepatol. 2021 Apr 28;9(2):194–202.
   PubMed Web of Science ®Google Scholar
• Choi JW, Jung JW, Park C, et al. A first-in-class small molecule targeting 17-beta-hydrocysteroid dehydrogenase 13 for the treatment of non-alcoholic steatohepatitis. J Hepatol. 2021 Jun;75(Supplement 2):S191–S866.
   Google Scholar
• Gane E, Schwabe C, Yoon KT, et al. ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH. J Hepatol. 2021;Supplement 2:S191–S866.
   Google Scholar
• Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol. 2004 Sep;165(3):901–912.
   PubMed Web of Science ®Google Scholar
• Lootens L, Van Eenoo P, Meuleman P, et al. Steroid metabolism in chimeric mice with humanized liver. Drug Test Anal. 2009 Nov;1(11–12):531–537.
   PubMed Web of Science ®Google Scholar
• Foster JR, Jacobsen M, Kenna G, et al. Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. Toxicol Pathol. 2012 Dec;40(8):1106–1116.
   PubMed Web of Science ®Google Scholar
• Samuelsson K, Pickup K, Sarda S, et al. Troglitazone metabolism and transporter effects in chimeric mice: a comparison between chimeric humanized and chimeric murinized FRG mice. Xenobiotica. 2014 Jan;44(2):186–195.
   PubMed Web of Science ®Google Scholar
• Bateman TJ, Reddy VG, Kakuni M, et al. Application of chimeric mice with humanized liver for study of human-specific drug metabolism. Drug Metab Dispos. 2014 Jun;42(6):1055–1065.
   PubMed Web of Science ®Google Scholar
• Barzi M, Pankowicz FP, Zorman B, et al. A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism. Nat Commun. 2017 Jun 28;8(1):39.
   PubMedGoogle Scholar
• Bissig-Choisat B, Alves-Bezerra M, Zorman B, et al. A human liver chimeric mouse model for non-alcoholic fatty liver disease. JHEP Rep. 2021 Jun;3(3):100281.
   PubMedGoogle Scholar
• Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009 May 14;459(7244):262–265.
   PubMed Web of Science ®Google Scholar
• Fujii M, Matano M, Toshimitsu K, et al. Human Intestinal Organoids Maintain Self-Renewal Capacity and Cellular Diversity in Niche-Inspired Culture Condition. Cell Stem Cell. 2018 Dec 6;23(6):787–793 e6.
   PubMed Web of Science ®Google Scholar
• Lancaster MA, Renner M, Martin CA, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013 Sep 19;501(7467):373–379.
   PubMed Web of Science ®Google Scholar
• Takasato M, Er PX, Chiu HS, et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature. 2015 Oct 22;526(7574):564–568.
   PubMed Web of Science ®Google Scholar
• Huch M, Gehart H, van Boxtel R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015 Jan 15;160(1–2):299–312.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu H, Zhang M, et al. One-step synthesis of composite hydrogel capsules to support liver organoid generation from hiPSCs. Biomater Sci. 2020 Oct 7;8(19):5476–5488.
   PubMed Web of Science ®Google Scholar
• Ouchi R, Togo S, Kimura M, et al. Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids. Cell Metab. 2019 Aug 6;30(2):374–384 e6. ** In this study the authors developed a new organoid culture method recapitulating the progressive stepwise nature of steatohepatitis pathology including steatosis, inflammation, and fibrosis.
   PubMed Web of Science ®Google Scholar
• Ramli MNB, Lim YS, Koe CT, et al. Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease. Gastroenterology. 2020 Oct;159(4):1471–1486 e12.
   PubMed Web of Science ®Google Scholar
• Grimaudo S, Pipitone RM, Pennisi G, et al. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2020 Apr;18(4):935–944 e3.
   PubMed Web of Science ®Google Scholar
• Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011 Apr 27;305(16):1659–1668.
   PubMed Web of Science ®Google Scholar
• Kuchay MS, Krishan S, Mishra SK, et al. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized Controlled Trial (E-LIFT Trial). Diabetes Care. 2018 Aug;41(8):1801–1808.
   PubMed Web of Science ®Google Scholar
• Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011 May;54(5):1011–1019.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016 Feb 13;387(10019):679–690.
   PubMed Web of Science ®Google Scholar
• Eslami L, Merat S, Malekzadeh R, et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013 Dec;27(12):CD008623.
   Google Scholar
• Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013 Dec;58(6):1941–1952.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956–965.
   PubMed Web of Science ®Google Scholar
• Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011 Jan;106(1):71–77.
   PubMed Web of Science ®Google Scholar
• Cespiati A, Youngson NA, Tourna A, et al. Genetics and Epigenetics in the Clinic: precision Medicine in the Management of Fatty Liver Disease. Curr Pharm Des. 2020;26(10):998–1009. ** A comprehensive review reporteing the genetic and epigenetic factors playing a key role in NAFLD severity.
   PubMed Web of Science ®Google Scholar
• Nobili V, Bedogni G, Donati B, et al. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food. 2013 Oct;16(10):957–960.
   PubMed Web of Science ®Google Scholar
• Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5–6):533–540.
   PubMed Web of Science ®Google Scholar
• Chery J. RNA therapeutics: rNAi and antisense mechanisms and clinical applications. Postdoc J. 2016 Jul;4(7):35–50.
   PubMedGoogle Scholar
• Sharma VK, Watts JK. Oligonucleotide therapeutics: chemistry, delivery and clinical progress. Future Med Chem. 2015;7(16):2221–2242.
   PubMed Web of Science ®Google Scholar